Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M HORWITZ

Showing results (691-700 of 832) with videos related to

Pageof 84
Sort By:
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Practical Radiation Oncology|January 7, 2018
A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of lifeWilliam C Jackson, Robert T Dess, Dale W Litzenberg, et al.
The New England Journal of Medicine|August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapyJuanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Blood Advances|February 9, 2021
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell ProjectAndrei Shustov, Maria Elena Cabrera, Monica Civallero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
Pageof 84

Showing results (691-700 of 832) with videos related to

Sort By:
Pageof 84
Nature Medicine|January 9, 2024
Unanswered questions following reports of secondary malignancies after CAR-T cell therapyBruce L Levine, Marcelo C Pasquini, John E Connolly, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 19, 2021
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional ExperienceN Nora Bennani, Aung M Tun, Kenneth R Carson, et al.
Practical Radiation Oncology|January 7, 2018
A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of lifeWilliam C Jackson, Robert T Dess, Dale W Litzenberg, et al.
The New England Journal of Medicine|August 31, 2012
Intermittent androgen suppression for rising PSA level after radiotherapyJuanita M Crook, Christopher J O'Callaghan, Graeme Duncan, et al.
Blood Advances|February 9, 2021
ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell ProjectAndrei Shustov, Maria Elena Cabrera, Monica Civallero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)Daniel M Geynisman, Philip H Abbosh, Eric Ross, et al.
Blood Advances|January 25, 2024
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOPKurt S Bantilan, Alexandra N Smith, Matthew J Maurer, et al.
Haematologica|September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experienceGiulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Blood|February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphomaSven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
Pageof 84